Navigation Links
Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
Date:8/5/2013

NEW YORK, Aug. 5, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present at the Wedbush Securities Life Sciences Management Access Conference in New York on Tuesday, August 13, 2013 at 9:45 a.m. ET.  A live webcast of the company's presentation will be available on the "Events" section of Intercept's investor website at http://ir.interceptpharma.com. A replay of the presentation will also be archived and available on Intercept's website for 2 weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases, such as primary biliary cirrhosis, utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA) is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to DSP. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.


'/>"/>
SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
4. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. Intercept Pharmaceuticals Closes $30 Million Series C Financing
6. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
7. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
8. AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
9. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
11. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 ... BVXV) announced today that BiondVax,s CEO, Dr. Ron Babecoff ... in New York City . ... 10:30am at Pioneers 2016, a conference presented by Joseph ... Palace Hotel. The BiondVax presentation that Dr. Babecoff ...
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
Breaking Medicine Technology:
(Date:5/6/2016)... PRUSSIA, PA and LONDON, UK (PRWEB) , ... May 06, 2016 ... ... earn accolades for his success in changing the way the pharmaceutical industry conducts clinical ... list of the world’s most influential people in pharma, and he was honored as ...
(Date:5/6/2016)... ... May 06, 2016 , ... US Sports Camps has collaborated with State Rugby ... State University this summer. Employing world-class rugby figures, including former Team USA players and ... training on key fundamentals, match play, fitness and more. , “US Sports Camps is ...
(Date:5/6/2016)... ... May 06, 2016 , ... Innovations with Ed ... airing third quarter 2016, via Discovery Channel. Dates and show times TBA. , ... optimized drug discovery through innovative cellular analysis. In this segment, viewers will learn ...
(Date:5/6/2016)... ... ... Online HR/benefits platforms offer a range of benefits functions to employers of all ... “ The Rapid Emergence of Online Benefits Firms: Strategies for Health Plans and Brokers ... an accurate picture of online benefits today, and the possible risks and rewards. Featuring ...
(Date:5/6/2016)... ... ... Mark Black is a speaker, author, and life strategy coach who is spreading the ... help of his publisher Strategic Book Group and its subsidiary Publish on Demand Global ... a miracle: He needed a heart and double-lung transplant. From this came a life-changing transformation ...
Breaking Medicine News(10 mins):